

Human Fas Ligand (FASL) Antibodies and Positive Control

Cat. FASL12-S	Rabbit Anti-Human FASL Antiserum	SIZE: 100 ul
Cat. FASL12-A	Rabbit Anti Human FASL IgG (aff pure)	SIZE: 100 ug
Cat. FASL12-P	Human FASL Control/blocking peptide	SIZE: 100 ug

Apoptosis occurs not only during programmed cell death, but also during the death process induced by some cytotoxic T cells. A protein ligand, FASL, was identified that triggers cell death by binding to the cell surface receptor variously known as FAS or APT1 family of receptors that includes the 2 tumor necrosis factor (TNF) receptors. The FAS antigen is expressed not only in the cells of the immune system but also in the liver, lung, ovary, and heart, where its function is unclear. FAS ligand (soluble Fas Ligand (sFasL), TNFSF6, CD95L, Apo I Ligand, APTL; human 281-aa, ~ 32 kDa, chromosome 1q23) is a type II transmembrane protein that belongs to the tumor necrosis factor family. FASL is expressed in activated splenocytes and thymocytes, consistent with its involvement in T-cell-mediated. Like other members of the TNF family, the membrane-bound FasL can be cleaved by metalloproteinase to generate the soluble Fas ligand (sFasL), which is mainly a non-covalently linked homotrimer. It has been shown that the membrane-bound TNF- α and FasL are primary activators of their receptors. In contrast to soluble TNF- α , sFasL is much less cytotoxic. FasL may competitively inhibit the killing effect of FasL, indicating that the cleaving of FasL might be a mechanism to down-regulate FASL activities. Rat FasL shares 93.3% and 78% amino acid identity with that of mouse and human, respectively. FASL is alternative spliced into two forms: Defects in TNFSF6 are a cause of autoimmune lymphoproliferative syndrome (ALPS), also known as Canale-Smith syndrome (CSS), a childhood syndrome involving hemolytic anemia and thrombocytopenia.

Source of Antigen and Antibodies

Antigen	13-aa peptide of human FASL (gene accession # P48023) Designated (FASL12-P or control peptide) conjugated to KLH Epitope location ~ C-terminus, Extracellular
Ab Host/type	Rabbit, Polyclonal antiserum # FASL12-S and IgG, purified over antigen-agarose (Cat # FASL12-A) purified over antigen-agarose column
2-Ab	Cat # 20320, goat anti-rabbit IgG-HRP (AP, biotin, FITC conjugates also available).
-ve	Cat # 20009-1, Rabbit (non-immune) Serum IgG, purified, suitable for ELISA, Western, IHC as -ve control

Human soluble FASL (107-281 aa; mol wt ~20 Kda) was expressed in CHO and purified (>95%).

Form & Storage of Antibodies/Peptide Control

Antiserum (unpurified)

100ul solution lyophilized powder
Supplied in Buffer: 0.05% azide

Reconstitute powder in 100 ul PBS

Affinity pure IgG

100 ug/100ul solution lyophilized powder
Supplied in **Buffer:** PBS+0.1% BSA

Reconstitute powder in PBS at 1mg/ml

Control/blocking peptide

100 ug/100 ul solution lyophilized powder
Supplied in Buffer: PBS pH 7.5,

Reconstitute powder in PBS at 1 mg/ml.

Storage

Short-term: unopened, undiluted liquid vials at -200C and powder at 4oC or -20oC..

Long-term: at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

Stability: 6-12 months at -20oC or below.

Recommended Usage

Western Blotting (1:1K-5K) for antiserum and 1-2 ug/ml for aff pure IgG using Chemiluminescence technique).

ELISA: Control peptide can be used to coat ELISA plates at 1 ug/ml and detected with antibodies (1:10-50K for neat serum and 0.5-1 ug/ml for affinity pure).

Histochemistry & Immunofluorescence: Not tested.

Specificity & Cross-reactivity

Human FASL11-P sequence is 92% homologous with rat and mouse FASL. Control peptide, because of its low mol. Wt (<3 kDa), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10 ug control peptide per 1 ug of aff pure IgG or 1 ul antiserum) to confirm antibody specificity (see detailed protocol at:the web site).

General References: Mita E (1994) BBRC 204, 468-474; 2. Hakuno N (1996) Endocrinology 137, 1938-48; 3. Hahne M (1995) Intl. Immunol. 7, 1381-1386; 4. Suda T and Nagata S (1994) J Exp. Med. 179, 873-879; 5. Takahashi T (1994) Cell 76, 969-976

*This product is for In vitro research use only.